| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
As a cationic lipid transfection reagent, DOTAP mesylate does not have specific biological receptors as its primary targets. Its mechanism of action involves electrostatic interactions with negatively charged nucleic acids, forming stable complexes called liposomes. These liposomes can fuse with cell membranes, facilitating the delivery of genetic material into the cytoplasm. The compound's positive charge is essential for its interaction with nucleic acids and cellular membranes. Its primary applications are as a transfection reagent for molecular biology and gene therapy research.
|
|---|---|
| ln Vitro |
In vitro, DOTAP mesylate is used as a cationic lipid transfection reagent for the delivery of DNA, RNA, oligonucleotides, ribonucleoprotein particles, and proteins into cultured cells. It helps to avoid problems commonly associated with transfection, such as cytotoxicity and low efficiency. The compound exhibits good biocompatibility and low toxicity, which are critical factors for its use in biomedical research. Cellular assays typically evaluate its transfection efficiency, cytotoxicity, and ability to deliver various types of genetic material.
|
| ln Vivo |
In vivo, DOTAP mesylate is used in preclinical studies for gene therapy and drug delivery applications. Cationic liposomes containing DOTAP mesylate can be administered via various routes, including intravenous injection, to deliver therapeutic nucleic acids to target tissues. The compound's biocompatibility and low toxicity make it suitable for in vivo applications. Its ability to facilitate efficient delivery of genetic material has been demonstrated in various animal models. The compound is classified for research use only and is not intended for human therapeutic applications without further development.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typically performed with DOTAP mesylate, as it is a transfection reagent rather than a receptor-targeting agent. However, the compound's interaction with nucleic acids and cell membranes can be studied using biophysical techniques. A typical protocol involves preparing liposomes by mixing DOTAP mesylate with lipids in organic solvents, followed by solvent evaporation and hydration. Nucleic acids are complexed with the liposomes at various charge ratios. Complex formation is assessed by agarose gel electrophoresis or dye exclusion assays. Cellular uptake is evaluated using fluorescently labeled nucleic acids and flow cytometry or fluorescence microscopy.
|
| Cell Assay |
Cellular assays for DOTAP mesylate typically evaluate its transfection efficiency and cytotoxicity. A standard protocol involves culturing mammalian cell lines (e.g., HEK293, HeLa) in growth medium at 37°C with 5% CO₂. Cells are seeded in multi-well plates and allowed to reach 70-80% confluency. DOTAP mesylate liposomes complexed with reporter plasmids (e.g., GFP, luciferase) or siRNA are prepared at various charge ratios and added to cells. After 4-6 hours, the medium is replaced with fresh growth medium. Transfection efficiency is assessed after 24-48 hours by measuring reporter gene expression (e.g., fluorescence microscopy, luciferase assay). Cytotoxicity is assessed using MTT or LDH release assays.
|
| Animal Protocol |
In vivo animal studies for DOTAP mesylate typically evaluate its potential as a gene delivery vehicle. A common protocol involves preparing DOTAP mesylate liposomes complexed with therapeutic nucleic acids. The complexes are administered to rodents via intravenous, intratumoral, or intramuscular injection. Tissue distribution and gene expression are assessed by measuring reporter gene activity or therapeutic efficacy in disease models. Biodistribution studies may involve radiolabeling the liposomes or nucleic acids. Pharmacokinetics, toxicity, and immunogenicity are evaluated using standard assays. The compound's transfection efficiency and safety profile are assessed in appropriate animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for DOTAP mesylate is limited, as it is primarily a research reagent. The compound has a molecular weight of 758.2 g/mol and a molecular formula of C₄₃H₈₃NO₇S. It is a solid at room temperature and is typically stored at -20°C. When formulated as liposomes, its pharmacokinetics are determined by the liposome properties, including size, charge, and surface modification. Cationic liposomes are typically cleared by the reticuloendothelial system and accumulate in the liver and spleen. Specific ADME data for DOTAP mesylate is limited and depends on the formulation.
|
| Toxicity/Toxicokinetics |
DOTAP mesylate is generally considered to have low toxicity for in vitro transfection applications. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. Standard safety precautions include handling with appropriate personal protective equipment in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is limited. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
DOTAP mesylate (CAS 252769-92-9) is a cationic lipid transfection reagent with the molecular formula C₄₃H₈₃NO₇S. It is chemically defined as N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl sulfate. The compound is used for the formation of positively charged liposomes for gene delivery and drug delivery applications. It exhibits good biocompatibility and low toxicity. DOTAP mesylate is classified as a research-use-only compound and is available from multiple commercial suppliers. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent.
|
| Molecular Formula |
C43H83NO7S
|
|---|---|
| Molecular Weight |
758.19
|
| Exact Mass |
757.589
|
| CAS # |
252769-92-9
|
| PubChem CID |
5702610
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
37
|
| Heavy Atom Count |
52
|
| Complexity |
833
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC/C=C\CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC/C=C\CCCCCCCC.CS(=O)(=O)[O-]
|
| InChi Key |
APGRDDRQPNSEQY-LQDDAWAPSA-M
|
| InChi Code |
InChI=1S/C42H80NO4.CH4O3S/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-41(44)46-39-40(38-43(3,4)5)47-42(45)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2;1-5(2,3)4/h20-23,40H,6-19,24-39H2,1-5H3;1H3,(H,2,3,4)/q+1;/p-1/b22-20-,23-21-;
|
| Chemical Name |
2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;methanesulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: 33.33 mg/mL (43.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.30 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.30 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3189 mL | 6.5947 mL | 13.1893 mL | |
| 5 mM | 0.2638 mL | 1.3189 mL | 2.6379 mL | |
| 10 mM | 0.1319 mL | 0.6595 mL | 1.3189 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
